Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Mavorixafor in Participants With Hepatic Impairment
NCT06858696Phase 1Completed
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mavorixafor in WHIM syndrome (WHIM) (6 arms), sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Maximum Observed Plasma Concentration of Mavorixafor and Area Under the Serum Concentration Curve From Time Zero to the Last Measurable Concentration of Mavorixafor. Started Feb 2025; status: completed.
02
Drugs
mavorixafor
03
Conditions
WHIM syndrome (WHIM)
Beyond the preview
Go deeper on NCT06858696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858696.